- Home
- BKYI vs QNCX Comparison
BKYI vs QNCX Comparison
Compare BKYI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | QNCX |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.9M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BKYI | QNCX |
|---|---|---|
| Price | $0.62 | $1.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 147.3K | ★ 65.6M |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,302,984.00 | N/A |
| Revenue This Year | $50.61 | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.81 | N/A |
| 52 Week Low | $0.49 | $0.08 |
| 52 Week High | $1.97 | $4.55 |
Technical Indicators
Market Signals| Indicator | BKYI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 75.77 |
| Support Level | $0.51 | $0.10 |
| Resistance Level | $0.63 | $1.47 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 55.74 | 90.60 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.